Aquestive Therapeutics, Inc. (AQST)
Chart Events
Performance Outlook
| Previous Close | 0.8866 |
| Open | 0.9000 |
| Bid | 0.8791 x 1000 |
| Ask | 0.8781 x 800 |
| Day's Range | 0.8701 - 0.9099 |
| 52 Week Range | 0.6180 - 3.1900 |
| Volume | |
| Avg. Volume | 266,673 |
| Market Cap | 35.264M |
| Beta (5Y Monthly) | 3.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6580 |
| Earnings Date | Mar 06, 2023 - Mar 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.36 |
- Simply Wall St.
When Will Aquestive Therapeutics, Inc. (NASDAQ:AQST) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Aquestive Therapeutics...
- GlobeNewswire
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the coming months of FDA response to request for Libervant™ (diazepam) Buccal Film accelerated market access Expects preliminary unaudited cash and cash equivalents of approximately $27 million as of December 31, 2022 WARREN, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceu
- GlobeNewswire
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
FDA continues to indicate that the Company can conduct a comparability study rather than efficacy studiesFDA provides clear guidance on approvability expectations for pharmacokinetic (PK) performance and patient administration attributesCompany continues to anticipate a potential product launch in 2025 with an NDA submission in first half of 2024 WARREN, N.J., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company ad
